What is BIIB revenue?

Biogen Inc. (BIIB) reported $10.30B of revenue for the twelve months ended Sep 30, 2026. That is up 2.3% from the year before. Revenue for fiscal 2025 was $9.89B.

Yes. Biogen Inc. earned $347.50M in net income for the twelve months ended Sep 30, 2026, a net margin of 3.4%.

How much cash and debt does BIIB have?

Biogen Inc. reported $1.30B in cash and cash equivalents and $7.29B of debt on its most recent balance sheet in SEC filings.

How fast is BIIB revenue growing?

Biogen Inc.'s revenue changed +2.2% in fiscal 2025, to $9.89B. Its compound annual growth rate was -6.0% over 5 years and -0.8% over 10 years.

What is BIIB gross margin?

Biogen Inc.'s gross profit was $7.62B on $10.30B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 74.0%.

What is BIIB free cash flow?

Biogen Inc. generated $2.07B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $2.25B less capital expenditures.

What is BIIB earnings per share?

Diluted earnings per share were $2.32 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did BIIB last report financial results?

The latest statements here come from Biogen Inc.'s 10-Q filed on Oct 28, 2026, covering the period ended Sep 30, 2026.

Where does this BIIB financial data come from?

Quantisnow builds these statements from the structured XBRL data Biogen Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · BIIB

Biogen Inc. (BIIB) financials

For the twelve months ended Sep 30, 2026, Biogen Inc. reported $10.30B of revenue and $347.50M of net income.

Revenue, TTM: $10.30B
Revenue growth, YoY: +2.3%
Net income, TTM: $347.50M
Net income growth, YoY: -78.4%
Net margin: 3.4%
Free cash flow, TTM: $2.07B
EPS, diluted, TTM: $2.32
EPS growth, YoY: -78.8%
Cash: $1.30B
Total debt: $7.29B
P/E: 105.64
P/S: 3.57
Market cap: $36.71B

Annual revenue$9.89B

FY2016FY2025

Annual net income$1.29B

FY2016FY2025

Annual free cash flow$2.05B

FY2016FY2025

BIIB revenue and earnings growth

BIIB revenueQ3 2026$2.80B

Quarter YoY: +10.6%
QoQ: +2.5%
FY YoY: +2.2%
5Y CAGR: -6.0%
10Y CAGR: -0.8%

BIIB revenue was $2.80B in fiscal Q3 2026 (ended Sep 30, 2026), up 10.6% from a year earlier and up 2.5% from the prior quarter. For the full fiscal 2025 it was $9.89B, up 2.2% from fiscal 2024. Compound annual growth was -6.0% over 5 years and -0.8% over 10 years. It rose in 5 of the last 10 fiscal years.

BIIB net incomeQ3 2026-$20.60M

FY YoY: -20.8%
5Y CAGR: -20.2%
10Y CAGR: -9.6%

BIIB net income was -$20.60M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $466.50M a year earlier. For the full fiscal 2025 it was $1.29B, down 20.8% from fiscal 2024. Compound annual growth was -20.2% over 5 years and -9.6% over 10 years. It rose in 5 of the last 10 fiscal years.

BIIB EPSQ3 2026-$0.14

FY YoY: -21.4%
5Y CAGR: -18.7%
10Y CAGR: -5.4%

BIIB diluted EPS was -$0.14 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $3.17 a year earlier. For the full fiscal 2025 it was $8.79, down 21.4% from fiscal 2024. Compound annual growth was -18.7% over 5 years and -5.4% over 10 years.

BIIB free cash flowQ3 2026$600.40M

Quarter YoY: -51.0%
QoQ: +47.2%
FY YoY: -24.7%
5Y CAGR: -11.6%
10Y CAGR: -4.6%

BIIB free cash flow was $600.40M in fiscal Q3 2026 (ended Sep 30, 2026), down 51.0% from a year earlier and up 47.2% from the prior quarter. For the full fiscal 2025 it was $2.05B, down 24.7% from fiscal 2024. Compound annual growth was -11.6% over 5 years and -4.6% over 10 years. It rose in 5 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$9.89B	$9.68B	$9.84B	$10.17B	$10.98B	$13.44B	$14.38B	$13.45B	$12.27B	$11.45B
Cost of revenue	$2.40B	$2.31B	$2.53B	$2.28B	$2.11B	$1.81B	$1.96B	$1.82B	$1.63B	$1.48B
Gross profit	$7.49B	$7.37B	$7.30B	$7.90B	$8.87B	$11.64B	$12.42B	$11.64B	$10.64B	$9.97B
Research and development	$1.78B	$1.98B	$2.45B	$2.23B	$2.50B	$3.99B	$2.28B	$2.60B	$2.25B	$1.97B
Selling, general and admin	$2.43B	$2.40B	$2.55B	$2.40B	$2.67B	$2.50B	$2.37B	$2.11B	$1.93B	$1.95B
Operating income	-	-	-	-	$2.84B	$4.55B	$7.04B	$5.89B	$5.35B	$5.15B
Interest expense	$267.50M	$250.30M	$246.90M	$246.60M	$253.60M	$222.50M	$187.40M	$200.60M	$250.80M	$260.00M
Pre-tax income	$1.56B	$1.91B	$1.30B	$3.59B	$1.75B	$5.05B	$7.13B	$5.90B	$5.13B	$4.93B
Income tax	$263.60M	$273.80M	$135.30M	$632.80M	$52.50M	$992.30M	$1.16B	$1.43B	$2.46B	$1.24B
Net income	$1.29B	$1.63B	$1.16B	$3.05B	$1.56B	$4.00B	$5.89B	$4.43B	$2.54B	$3.70B
EPS, basic	$8.83	$11.21	$8.02	$20.96	$10.44	$24.86	$31.47	$21.63	$11.94	$16.96
EPS, diluted	$8.79	$11.18	$7.97	$20.87	$10.40	$24.80	$31.42	$21.58	$11.92	$16.93
Diluted shares	147.1M	145.9M	145.6M	146.0M	149.6M	161.3M	187.4M	205.3M	213.0M	218.8M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$3.01B	$2.38B	$1.05B	$3.42B	$2.26B	$1.33B	$2.91B	$1.22B	$1.57B	$2.33B
Receivables	$1.34B	$1.40B	$1.66B	$1.71B	$1.55B	$1.91B	$1.88B	$1.96B	$1.79B	$1.44B
Inventory	$2.17B	$2.46B	$2.53B	$1.34B	$1.35B	$1.07B	$804.20M	$929.90M	$902.70M	$1.00B
Current assets	$8.97B	$7.46B	$6.86B	$9.79B	$7.86B	$6.89B	$8.38B	$7.64B	$7.87B	$8.73B
Goodwill	$6.49B	$6.48B	$6.22B	$5.75B	$5.76B	$5.76B	$5.76B	$5.71B	$4.63B	$3.67B
Total assets	$29.44B	$28.05B	$26.84B	$24.55B	$23.88B	$24.62B	$27.23B	$25.29B	$23.65B	$22.88B
Current liabilities	$3.35B	$5.53B	$3.43B	$3.27B	$4.30B	$3.74B	$4.86B	$3.30B	$3.37B	$3.42B
Short-term debt	$0	$1.75B	$150.00M	$0	$999.10M	$0	$1.50B	$0	$3.20M	$4.70M
Long-term debt	-	-	-	-	-	-	-	-	$0	$16.40M
Total debt	$6.29B	$4.55B	$6.79B	$6.28B	$6.27B	$7.43B	$4.46B	$5.94B	$3.20M	$21.10M
Total liabilities	$11.18B	$11.33B	$12.05B	$11.17B	$12.92B	$13.93B	$13.90B	$12.26B	$11.05B	$10.75B
Shareholders' equity	$18.26B	$16.72B	$14.80B	$13.39B	$10.96B	$10.69B	$13.34B	$13.03B	$12.60B	$12.14B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$2.20B	$2.88B	$1.55B	$1.38B	$3.64B	$4.23B	$7.08B	$6.19B	$4.55B	$4.59B
Capital expenditures	$153.80M	$153.70M	$277.00M	$240.30M	$258.10M	$424.80M	$514.50M	$770.60M	$867.40M	$616.10M
Free cash flow	$2.05B	$2.72B	$1.27B	$1.14B	$3.38B	$3.81B	$6.56B	$5.42B	$3.68B	$3.97B
Investing cash flow	-$1.37B	-$799.20M	-$4.10B	$1.58B	-$563.70M	-$608.60M	$470.50M	-$2.05B	-$2.96B	-$2.48B
Financing cash flow	-$301.90M	-$683.50M	$149.30M	-$1.75B	-$2.09B	-$5.27B	-$5.86B	-$4.47B	-$2.38B	-$1.05B
Share repurchases	-	$0	$0	$750.00M	$1.80B	$6.68B	$5.87B	$4.35B	$1.37B	$1.00B
Stock-based compensation	$290.80M	$291.20M	$264.20M	$254.10M	$238.60M	$198.30M	$182.30M	$157.50M	$128.00M	$154.80M
Depreciation and amortization	$779.90M	$673.20M	$494.80M	$518.40M	$487.70M	$457.20M	$464.70M	$650.50M	$1.08B	$682.70M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	2.2%	-1.6%	-3.3%	-7.4%	-18.3%	-6.5%	6.9%	9.6%	7.2%	6.4%
Net income growth, YoY	-20.8%	40.6%	-61.9%	95.8%	-61.1%	-32.1%	32.9%	74.5%	-31.4%	4.4%
EPS growth, YoY	-21.4%	40.3%	-61.8%	100.7%	-58.1%	-21.1%	45.6%	81.0%	-29.6%	10.4%
Gross margin	75.7%	76.1%	74.2%	77.6%	80.8%	86.6%	86.4%	86.5%	86.7%	87.1%
Operating margin	-	-	-	-	25.9%	33.8%	49.0%	43.8%	43.6%	45.0%
Net margin	13.1%	16.9%	11.8%	29.9%	14.2%	29.8%	41.0%	32.9%	20.7%	32.3%
Free cash flow margin	20.7%	28.1%	12.9%	11.2%	30.8%	28.3%	45.7%	40.3%	30.0%	34.7%
Return on equity	7.1%	9.8%	7.8%	22.8%	14.2%	37.4%	44.1%	34.0%	20.2%	30.5%
Return on assets	4.4%	5.8%	4.3%	12.4%	6.5%	16.3%	21.6%	17.5%	10.7%	16.2%
Current ratio	2.68	1.35	2.00	2.99	1.83	1.84	1.72	2.32	2.34	2.55
Debt to equity	0.34	0.27	0.46	0.47	0.57	0.69	0.33	0.46	0.00	0.00

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$2.80B	$2.74B	$2.48B	$2.28B	$2.53B	$2.65B	$2.43B	$2.45B	$2.47B	$2.46B	$2.29B	$2.39B
Cost of revenue	$748.40M	$776.90M	$661.00M	$495.50M	$674.40M	$605.00M	$629.30M	$583.50M	$638.70M	$546.00M	$542.20M	$618.30M
Gross profit	$2.06B	$1.96B	$1.82B	$1.78B	$1.86B	$2.04B	$1.80B	$1.87B	$1.83B	$1.92B	$1.75B	$1.77B
Research and development	$574.00M	$529.60M	$539.00M	$509.40M	$436.10M	$399.00M	$434.10M	$513.30M	$516.20M	$505.40M	$445.40M	$554.30M
Selling, general and admin	$752.00M	$709.70M	$607.30M	$682.50M	$594.80M	$583.80M	$572.50M	$680.00M	$588.40M	$553.80M	$581.50M	$608.50M
Interest expense	$87.50M	$82.30M	$67.60M	$67.50M	$67.40M	$72.60M	$60.00M	$60.00M	$59.80M	$61.30M	$69.20M	$71.50M
Pre-tax income	-$9.00M	$132.40M	$377.70M	-$56.00M	$557.30M	$744.00M	$311.20M	$291.50M	$451.00M	$698.70M	$464.80M	$291.60M
Income tax	$11.60M	$34.90M	$58.20M	-$7.10M	$90.80M	$109.20M	$70.70M	$24.80M	$62.50M	$115.10M	$71.40M	$42.70M
Net income	-$20.60M	$97.50M	$319.50M	-$48.90M	$466.50M	$634.80M	$240.50M	$266.70M	$388.50M	$583.60M	$393.40M	$249.70M
EPS, basic	-$0.14	$0.66	$2.17	-$0.33	$3.18	$4.33	$1.65	$1.82	$2.67	$4.01	$2.71	$1.71
EPS, diluted	-$0.14	$0.66	$2.15	-$0.35	$3.17	$4.33	$1.64	$1.82	$2.66	$4.00	$2.70	$1.70
Diluted shares	147.8M	148.7M	148.4M	-	147.1M	146.7M	146.6M	-	146.1M	145.9M	145.9M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$1.30B	$1.28B	$3.38B	$3.01B	$3.86B	$2.76B	$2.60B	$2.38B	$1.70B	$1.91B	$1.07B	$1.05B
Receivables	-	-	-	$1.34B	-	-	-	$1.40B	-	-	-	$1.66B
Inventory	$2.22B	$2.38B	$1.95B	$2.17B	$2.21B	$2.27B	$2.27B	$2.46B	$2.47B	$2.51B	$2.52B	$2.53B
Current assets	$7.58B	$7.31B	$9.19B	$8.97B	$8.94B	$7.97B	$7.63B	$7.46B	$6.83B	$7.11B	$6.76B	$6.86B
Goodwill	$6.99B	$6.99B	$6.49B	$6.49B	$6.49B	$6.49B	$6.48B	$6.48B	$6.49B	$6.23B	$6.23B	$6.22B
Total assets	$32.05B	$32.09B	$29.48B	$29.44B	$29.21B	$28.33B	$28.03B	$28.05B	$28.31B	$26.80B	$26.57B	$26.84B
Current liabilities	$3.90B	$3.92B	$3.00B	$3.35B	$3.29B	$3.18B	$5.30B	$5.53B	$5.42B	$3.11B	$3.22B	$3.43B
Short-term debt	-	-	-	$0	-	-	-	$1.75B	-	-	-	$150.00M
Total debt	$7.29B	$7.29B	$6.29B	$6.29B	$6.29B	$6.28B	$4.55B	$4.55B	$4.55B	$6.29B	$6.29B	$6.79B
Total liabilities	$13.13B	$13.24B	$10.83B	$11.18B	$11.00B	$10.70B	$11.05B	$11.33B	$11.95B	$10.91B	$11.35B	$12.05B
Shareholders' equity	$18.92B	$18.85B	$18.65B	$18.26B	$18.21B	$17.63B	$16.98B	$16.72B	$16.36B	$15.89B	$15.21B	$14.80B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$640.80M	$448.90M	$645.50M	$511.90M	$1.27B	$160.90M	$259.30M	$760.90M	$935.60M	$625.80M	$553.20M	$12.50M
Capital expenditures	$40.40M	$40.90M	$51.20M	$43.90M	$46.20M	$26.60M	$37.10M	$39.30M	$35.00M	$33.50M	$45.90M	$65.20M
Free cash flow	$600.40M	$408.00M	$594.30M	$468.00M	$1.23B	$134.30M	$222.20M	$721.60M	$900.60M	$592.30M	$507.30M	-$52.70M
Investing cash flow	-$222.10M	-$3.84B	-$209.50M	-$1.23B	-$35.10M	-$57.00M	-$47.30M	-$18.60M	-$1.18B	$466.50M	-$66.00M	-$652.30M
Financing cash flow	-$393.80M	$1.30B	-$43.80M	-$137.00M	-$130.20M	-$11.70M	-$23.00M	$7.90M	-$6.60M	-$245.20M	-$439.60M	-$646.10M
Share repurchases	-	-	-	-	-	-	-	-	-	-	-	$0
Stock-based compensation	$81.50M	$77.40M	$84.00M	$59.60M	$75.30M	$74.90M	$81.00M	$75.10M	$72.70M	$70.60M	$72.80M	$54.90M
Depreciation and amortization	$241.10M	$236.10M	$204.40M	$200.20M	$202.20M	$194.30M	$183.20M	$184.00M	$182.80M	$158.90M	$147.50M	$140.10M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	10.6%	3.4%	1.9%	-7.1%	2.8%	7.3%	6.1%	2.9%	-2.5%	0.4%	-7.0%	-6.2%
Net income growth, YoY	-	-84.6%	32.8%	-	20.1%	8.8%	-38.9%	6.8%	-	-1.4%	1.4%	-54.6%
EPS growth, YoY	-	-84.8%	31.1%	-	19.2%	8.3%	-39.3%	7.1%	-	-1.7%	1.1%	-54.4%
Gross margin	73.3%	71.6%	73.3%	78.3%	73.4%	77.1%	74.1%	76.2%	74.1%	77.8%	76.3%	74.1%
Net margin	-0.7%	3.6%	12.9%	-2.1%	18.4%	24.0%	9.9%	10.9%	15.8%	23.7%	17.2%	10.5%
Free cash flow margin	21.4%	14.9%	24.0%	20.5%	48.4%	5.1%	9.1%	29.4%	36.5%	24.0%	22.1%	-2.2%
Current ratio	1.95	1.87	3.06	2.68	2.72	2.50	1.44	1.35	1.26	2.29	2.10	2.00
Debt to equity	0.39	0.39	0.34	0.34	0.35	0.36	0.27	0.27	0.28	0.40	0.41	0.46

Source: XBRL data Biogen Inc. files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BIIB peers

Company	Revenue	Growth	Net income	Net margin	Market cap
BIIB	$10.30B	+2.3%	$347.50M	3.4%	$36.71B
AMGNAmgen Inc.	$38.90B	+8.2%	$9.39B	24.1%	$249.05B
GILDGilead Sciences Inc.	$30.99B	+6.5%	-$3.86B	-12.5%	$207.00B
MRNAModerna Inc.	$2.52B	+13.1%	-$2.79B	-110.5%	$101.48B
ARGXargenx SE	$4.25B	+88.6%	$1.29B	30.4%	$57.55B
RVMDRevolution Medicines Inc.	$0	-	-$1.13B	-	$41.59B
BNTXBioNTech SE	€2.87B	+4.3%	-€1.14B	-39.6%	$21.98B
EXELExelixis Inc.	$2.50B	+9.1%	$885.14M	35.5%	$16.98B
NBIXNeurocrine Biosciences Inc.	$3.70B	+38.0%	$702.50M	19.0%	$16.66B

BIIB FAQ

9 questions

What is BIIB revenue?
Biogen Inc. (BIIB) reported $10.30B of revenue for the twelve months ended Sep 30, 2026. That is up 2.3% from the year before. Revenue for fiscal 2025 was $9.89B.
Is BIIB profitable?
Yes. Biogen Inc. earned $347.50M in net income for the twelve months ended Sep 30, 2026, a net margin of 3.4%.
How much cash and debt does BIIB have?
Biogen Inc. reported $1.30B in cash and cash equivalents and $7.29B of debt on its most recent balance sheet in SEC filings.
How fast is BIIB revenue growing?
Biogen Inc.'s revenue changed +2.2% in fiscal 2025, to $9.89B. Its compound annual growth rate was -6.0% over 5 years and -0.8% over 10 years.
What is BIIB gross margin?
Biogen Inc.'s gross profit was $7.62B on $10.30B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 74.0%.
What is BIIB free cash flow?
Biogen Inc. generated $2.07B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $2.25B less capital expenditures.
What is BIIB earnings per share?
Diluted earnings per share were $2.32 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did BIIB last report financial results?
The latest statements here come from Biogen Inc.'s 10-Q filed on Oct 28, 2026, covering the period ended Sep 30, 2026.
Where does this BIIB financial data come from?
Quantisnow builds these statements from the structured XBRL data Biogen Inc. files with the SEC. It is provided for information only and is not investment advice.